Company Description
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United States, Croatia, Bulgaria, Ireland, the Cayman Islands, the UAE, the United Kingdom, and Cyprus.
The company offers medicines, OTC medicines, nutraceutical products, vitamins, minerals, and dietary health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.
It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).
In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names.
Other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag to promote peaceful sleep; Otikon ear drops, which is a Class II medical device in the form of ear drops; and Bio-bebe, an organic infant care and nutrition brand.
The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies, and independent specialty distributors.
Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
| Country | Greece |
| Founded | 2009 |
| IPO Date | Dec 13, 2013 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Grigorios Siokas |
Contact Details
Address: 5 Agiou Georgiou Str, Pilea Thessaloniki, 55438 Greece | |
| Phone | 312 536 3102 |
| Website | cosmosholdingsinc.com |
Stock Details
| Ticker Symbol | COSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001474167 |
| CUSIP Number | 221413206 |
| ISIN Number | US2214133058 |
| Employer ID | 27-0611758 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Grigorios Siokas | Chairman and Chief Executive Officer |
| Georgios Terzis | Chief Financial Officer |
| Nikolaos Bardakis | Chief Operating Officer |
| Demetrios G. Demetriades | Secretary and Independent Director |
| Prof. Dimitrios Trafalis | Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 6, 2025 | SCHEDULE 13G | Filing |
| Feb 28, 2025 | SCHEDULE 13D/A | Filing |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 29, 2025 | SCHEDULE 13D/A | Filing |